VRAX Overview

UiPath Financial Results: UiPath Inc. shares rose 8.7% in pre-market trading after reporting third-quarter adjusted earnings of 16 cents per share and revenue of $411.11 million, both exceeding estimates.

Other Gainers: Several stocks saw significant pre-market gains, including Polyrizon Ltd (+158.1%), Nauticus Robotics, Inc (+34%), and Picard Medical, Inc (+22.3%), driven by positive news and developments.

Notable Losers: Virax Biolabs Group Ltd fell 16.2% after announcing a private placement, while Treasure Global Inc declined 13.3% following a reverse stock split and Nasdaq delisting notification.

Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like Axogen, Inc and Hyster-Yale, Inc also experiencing notable increases.

Share Purchase Agreement: Virax Biolabs Group Limited has entered into an agreement to sell 12.5 million shares at $0.40 each, aiming for gross proceeds of $5 million.

Use of Proceeds: The company plans to utilize the net proceeds for working capital and general corporate purposes, with the private placement expected to close around December 4, 2025.

Regulatory Compliance: Virax Biolabs will complete necessary SEC paperwork within 45 days to enable investors to legally resell their shares.

Stock Performance: Following a significant increase of 75.11% in the previous trading session, the stock is down 16.16% in pre-market trading.

Stock Performance: Virax Biolabs Group Ltd (NASDAQ: VRAX) shares fell 12.79% to $0.60 in after-hours trading, despite closing at $0.69, a 75.11% increase for the day. The stock has declined 68.87% year-to-date.

Private Placement Announcement: The company announced a private placement of 12.5 million ordinary shares at $0.40 each, expected to raise $5 million before fees, with H.C. Wainwright & Co. as the exclusive placement agent.

Warrant Modifications: The offering includes preferred investment options priced at $0.40 per share, with modifications to existing Series A and B options to match the new price and extend their expiration to five years.

Use of Proceeds: Virax plans to use the net proceeds from the private placement for working capital and general corporate purposes, with the transaction expected to close soon, subject to customary conditions.